The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Abstract
To test the hypothesis that maximal androgen blockade improves the effectiveness of the treatment of prostatic cancer, we conducted a randomized, double-blind trial in patients with disseminated, previously untreated prostate cancer (stage D2). All 603 men received leuprolide, an analogue of gonadotropin-releasing hormone that inhibits the release of gonadotropins, in combination with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus. As compared with the 300 patients receiving leuprolide and placebo, the 303 patients randomly assigned to receive leuprolide and flutamide had a longer progression-free survival (16.5 vs. 13.9 months; P = 0.039) and an increase in the median length of survival (35.6 vs. 28.3 months; P = 0.035). The differences between the treatments were particularly evident for men with minimal disease and good performance status; however, further studies should be conducted in this subgroup. Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade, when leuprolide alone often produces a painful flare in the disease. We conclude that in patients with advanced prostate cancer, treatment with leuprolide and flutamide is superior to treatment with leuprolide alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies have shown that despite treatment with medical or surgical castration, prostate cancers continue to have sufficient levels of androgens to drive tumor growth.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [33]
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
The Endocrinology and Developmental Biology of the Prostate*
CUNHA, G. R., DONJACOUR, A. A., COOKE, P. S., MEE, H., BIGSBY, R. M., HIGGINS, S. J., & SUGIMURA, Y. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-3-338 · Cited by 1,036
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c · Cited by 597
Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., & Scheres, J. (1986) · The Prostate · doi:10.1002/pros.2990090306 · Cited by 407
Isaacs, J. T., & Coffey, D. S. (1981) · PubMed · Cited by 371
Complete androgen blockade for the treatment of prostate cancer.
Labrie, F., Dupont, A., & Bèlanger, A. (1985) · PubMed · Cited by 281
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., & Friedman, M. A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.827 · Cited by 267
Self-citationHormonal Therapy of Prostatic Cancer
SCOTT, W. W., MENON, M., & WALSH, P. C. (1980) · Cancer · doi:10.1002/cncr.1980.45.s7.1929 · Cited by 192
Research works printed but not linked: 9
- Huggins, 1941, Cancer Res, 1, 293
- Sufrin, 1976, Invest Ural, 13, 429
- Coffey, 1981, Urology, 17, 17
- Wake, 1982, Cancer Res, 42, 4131
- Isaacs, 1982, Cancer Res, 42, 2353
- Brendler, 1962, Cancer Chemother Rep, 16, 323
- Isaacs, 1981, Cancer Res, 41, 5070
- Ellis, 1985, Cancer Res, 45, 6041
- Geller J, Albert JD. Antiandrogens and small doses of estrogen therapy as the preferred treatment for prostatic cancer. In: Hormones and cancer. New York: Raven Press, 1984.
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
“Back pain 233 (30) 44 (6) 3 (<1) 129 (33) 37 (9) 1 (<1)”
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationNatural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Self-citation
Metadata
- Authors
- Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J.
- Affiliations
- University of Colorado Denver (US)
- National Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1989-08-17
- Volume
- 321
- Issue
- 7
- Pages
- 419-424
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014145760
- Cited by
- 1,464
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 17 · 2020: 19 · 2019: 25 · 2018: 20 · 2017: 25 · 2016: 30 · 2015: 43 · 2014: 49 · 2013: 50 · 2012: 43
- FWCI
- 62.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- leuprolide, flutamide, androgen deprivation therapy, combined androgen blockade, prostate cancer, advanced prostate cancer, progression-free survival, survival, GnRH analogues, nonsteroidal antiandrogens
- MeSH terms
- Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Clinical Trials as Topic, Double-Blind Method, Drug Therapy, Combination, Flutamide, Humans, Gonadotropin-Releasing Hormone, Male, Middle Aged, Prostatic Neoplasms, Random Allocation, Leuprolide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma. https://app.cochat.ai/papers/10.1056/nejm198908173210702
- The paper
- Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989). A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejm198908173210702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.